Business
IMNN: First Site Activated for Phase 3 OVATION 3 Trial…
By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Business Update First Site Activated for Phase 3 OVATION 3 Trial of IMNN-001 in Ovarian Cancer On May 8, 2025, Imunon, Inc. (NASDAQ:IMNN) announced that the first trial site for the Phase 3 OVATION 3 trial has been activated and is ready to begin enrolling patients. During the quarterly update conference call, management indicated
About this update from Imunon, Inc.
[{"type":"text","content":"By David Bautz, PhD","length":19,"tagName":"p"},{"type":"text","content":"NASDAQ:IMNN","length":11,"tagName":"p"},{"type":"text","content":"READ THE FULL IMNN RESEARCH REPORT","length":34,"tagName":"p"},{"type":"text","content":"Business Update","length":15,"tagName":"p"},{"type":"text","content":"First Site Activated for Phase 3 OVATION 3 Trial of IMNN-001 in Ovarian Cancer","length":78,"tagName":"p"},{"type":"text","content":"On May 8, 2025, Imunon, Inc. (NASDAQ:IMNN) announced that the first trial site for the Phase 3 OVATION 3 trial has been activated and is ready to begin enrolling patients. During the quarterly update conference call, management indicated that a second site will be activated this week, with the eventual goal being a total of 45 sites.","length":335,"tagName":"p"},{"type":"text","content":"The following slide provides the overall design of the trial. Eligible patients will have either Stage IIIc or IV advanced ovarian cancer and will be randomized to receive neoadjuvant chemotherapy (NACT), interval debulking surgery, adjuvant chemotherapy with or without IMNN-001. Patients who are positive for homologous recombination deficiency (HDR) are also eligible and will receive poly ADP-ribose polymerase (PARP) inhibitor therapy as part of standard-of-care (SOC) maintenance therapy. The primary endpoint is overall survival (OS), with secondary endpoints evaluating surgical response score, chemotherapy response score, clinical response (ORR), and time to second-line treatment.","length":691,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":1532,"height":928,"url":"https://media.zenfs.com/en/scr.zacks.com/7bd950043f33f92250d289e674433c71"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DPYo9JOi25__PLrCTADfpQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU4MjtjZj13ZWJw/https://media.zenfs.com/en/scr.zacks.com/7bd950043f33f92250d289e674433c71","width":960,"height":582},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/yLaOHHyUQyueb4RiPxnW4g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xNDU0O2NmPXdlYnA-/https://media.zenfs.com/en/scr.zacks.com/7bd950043f33f92250d289e674433c71","width":1200,"height":727}}},{"type":"text","content":"The company is utilizing a statistical design with two planned interim analyses. The goal is to...